Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1967 2
1969 1
1973 1
1976 2
1979 2
1981 4
1983 2
1984 3
1985 2
1986 5
1987 5
1988 7
1989 6
1990 9
1991 4
1992 8
1993 16
1994 5
1995 27
1996 21
1997 16
1998 15
1999 14
2000 12
2001 19
2002 17
2003 15
2004 16
2005 14
2006 22
2007 22
2008 23
2009 21
2010 23
2011 25
2012 22
2013 29
2014 32
2015 28
2016 29
2017 36
2018 37
2019 42
2020 40
2021 35
2022 28
2023 27
2024 41
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Results by year

Filters applied: . Clear all
Page 1
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Watanabe J, et al. Among authors: takashima a. JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428. JAMA. 2023. PMID: 37071094 Free PMC article. Clinical Trial.
Current Targeted Therapy for Metastatic Colorectal Cancer.
Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Ohishi T, et al. Among authors: takashima a. Int J Mol Sci. 2023 Jan 15;24(2):1702. doi: 10.3390/ijms24021702. Int J Mol Sci. 2023. PMID: 36675216 Free PMC article. Review.
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Mori I, Yamanaka K, Hihara M, Soeda J, Misumi T, Yamamoto K, Yamashita R, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Shitara K, et al. Among authors: takashima a. Nat Med. 2024 Mar;30(3):730-739. doi: 10.1038/s41591-023-02791-w. Epub 2024 Feb 12. Nat Med. 2024. PMID: 38347302 Free PMC article.
Review: Chronic endometritis and its effect on reproduction.
Kimura F, Takebayashi A, Ishida M, Nakamura A, Kitazawa J, Morimune A, Hirata K, Takahashi A, Tsuji S, Takashima A, Amano T, Tsuji S, Ono T, Kaku S, Kasahara K, Moritani S, Kushima R, Murakami T. Kimura F, et al. Among authors: takashima a. J Obstet Gynaecol Res. 2019 May;45(5):951-960. doi: 10.1111/jog.13937. Epub 2019 Mar 6. J Obstet Gynaecol Res. 2019. PMID: 30843321 Review.
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, Denda T, Watanabe J, Shinozaki K, Baba H, Asayama M, Hasegawa S, Masuishi T, Nakata K, Tsukamoto S, Katayama H, Nakamura K, Fukuda H, Kanemitsu Y, Shimada Y; Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG). Takashima A, et al. J Clin Oncol. 2024 Nov 20;42(33):3967-3976. doi: 10.1200/JCO.23.02722. Epub 2024 Aug 26. J Clin Oncol. 2024. PMID: 39186709 Clinical Trial.
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.
Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T. Sunami K, et al. Among authors: takashima a. JAMA Oncol. 2024 Jan 1;10(1):95-102. doi: 10.1001/jamaoncol.2023.5120. JAMA Oncol. 2024. PMID: 38032680 Free PMC article.
Tau Oligomers.
Maeda S, Takashima A. Maeda S, et al. Among authors: takashima a. Adv Exp Med Biol. 2019;1184:373-380. doi: 10.1007/978-981-32-9358-8_27. Adv Exp Med Biol. 2019. PMID: 32096050 Review.
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Raghav K, et al. Among authors: takashima a. Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5. Lancet Oncol. 2024. PMID: 39116902 Clinical Trial.
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
Takashima A, García-Alfonso P, Manneh R, Beşen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, Yoshino T, Kim TW, Cui K, Li C, Jain R, Adelberg D, Taieb J. Takashima A, et al. Eur J Cancer. 2024 Jul;205:114036. doi: 10.1016/j.ejca.2024.114036. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38749110 Free article. Clinical Trial.
Dual-wavelength spiral interferometry.
Tokizane Y, Takashima A, Hase E, Yasui T. Tokizane Y, et al. Among authors: takashima a. Opt Lett. 2024 Jun 15;49(12):3516-3519. doi: 10.1364/OL.525588. Opt Lett. 2024. PMID: 38875659
757 results